丁苯酞氯化钠注射液治疗内囊预警综合征的效果  

Effective study of butylphthalide sodium chloride injection in the treatment of capsular warning syndrome

作　　者：田广平[1] 邹宁[1] 马颖 TIAN Guang-ping;ZOU Ning;MA Ying(Department of Neurology,Qinhuangdao Second Hospital,Hebei Qinhuangdao 066600,China)

机构地区：[1]秦皇岛市第二医院神经内科,河北秦皇岛066600

出　　处：《临床药物治疗杂志》2022年第9期77-81,共5页Clinical Medication Journal

基　　金：秦皇岛市市级科技计划重点项目(201703A127)。

摘　　要：目的观察丁苯酞氯化钠注射液治疗内囊预警综合征的效果。方法纳入2017年9月至2021年8月秦皇岛市第二医院收治的内囊预警综合征患者70例,通过随机数字表法分为观察组(n=35)和对照组(n=35)。对照组接受溶栓、抗血小板和调脂等常规治疗,合并高血压、糖尿病、冠心病者予以相应治疗,观察组在对照组基础上给予丁苯酞氯化钠注射液治疗,两组均治疗14 d,并随访90 d。比较治疗前、治疗14 d后两组患者神经功能、日常生活能力、血清细胞因子水平,随访90 d预后情况及随访期间不良反应发生情况。结果治疗14 d后,观察组总有效率高于对照组(91.43%比71.43%,P<0.05);两组患者美国国立卫生研究院卒中量表(NIHSS)评分[观察组:治疗前为(5.90±1.07)分,治疗后为(2.45±1.43)分;对照组:治疗前为(5.95±1.00)分,治疗后为(3.45±1.15)分]、血清S100B蛋白(S100B)[观察组:治疗前为(0.31±0.08)μg/L,治疗后为(0.15±0.05)μg/L;对照组治疗前为(0.32±0.08)μg/L,治疗后为(0.23±0.09)μg/L]、基质金属蛋白酶9(MMP-9)[观察组:治疗前为(318.66±38.24)ng/L,治疗后为(165.25±24.64)ng/L;对照组:治疗前为(311.62±41.35)ng/L,治疗后为(257.81±29.74)ng/L]、缺血修饰白蛋白(IMA)[观察组:治疗前为(77.12±8.64)μmol/L,治疗后为(52.65±6.53)μmol/L;对照组:治疗前为(78.88±8.38)μmol/L,治疗后为(65.32±6.81)μmol/L]水平均较治疗前降低,且观察组低于对照组;Barthel指数(BI)均升高,且观察组高于对照组(P<0.05)。随访90 d两组患者进展为脑卒中情况比较,差异无统计学意义(P>0.05),但观察组预后良好比例高于以对照组(94.29%比82.86%,P<0.05)。随访期间两组患者均未发生体位性低血压、发热、横纹肌溶解征、头痛、颅内出血、胸痛、胃肠道症状等明显不良反应。结论丁苯酞氯化钠注射液治疗内囊预警综合征疗效确切,安全性高。Objective To analyze the curative effect of butylphthalide sodium chloride injection on the treatment of capsule warning syndrome.Methods A total of 70 patients with capsule warning syndrome admitted to the Second Hospital of Qinhuangdao city divided into the observation group(n=35)and the control group(n=35)by random number table method from September 2017 to August 2021.The control group received conventional treatments such as thrombolysis,antiplatelet and lipid-lowering drugs,and those with hypertension,diabetes,and coronary heart disease were treated accordingly.The observation group received butylphthalide treatment on the basis of the control group.Both groups were treated for 14 d,and were followed up to 90 d.The neurological function,activities of daily living,serum cytokine levels,prognosis and adverse reactions during the 90 day follow-up were compared between the two groups before treatment and 14 days after treatment.Results The total effective rate after 14 d of treatment in the observation group was significantly higher than that in the control group(91.43%vs 71.43%,P<0.05).The National Institutes of Health Stroke Scale(NIHSS)score:The scores of the observation group and the control group before and after treatment were(5.90±1.07)vs(2.45+1.43);(5.95±1.00)vs(3.45±1.15)respectively.The levels of the serum S100B protein(S100B):the observation group:the levels of the observation group and the control group before and after treatment were(0.31±0.08)vs(0.15±0.05);(0.32±0.08)vs(0.23±0.09).The level of the matrix metalloproteinase-9(MMP-9):the observation group:the scores of observation group and control group before and after treatment were(318.66±38.24)vs(165.25±24.64);(311.62±41.35)vs(257.81±29.74).The level of the serum ischemia-modified albumin(IMA):observation group:the levels of the observation group and the control group before and after treatment were(77.12±8.64)vs(52.65±6.53);(78.88±8.38)vs(65.32±6.81).Conclusion Butylphthalide in the treatment of capsular warning syndrome has defi

关 键 词：内囊预警综合征 丁苯酞 神经功能 安全性 

分 类 号：R971[医药卫生—药品]